secwatch / observer
8-K filed May 9, 2023, 7:59 PM ET ticker DTIL CIK 0001357874
other confidence high sentiment neutral materiality 0.10

Precision BioSciences stockholders elect Amoroso and Germano as Class I directors

PRECISION BIOSCIENCES INC

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PRECISION BIOSCIENCES INC shareholders approved Election of two Class I directors to serve until the Company's annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified. at the 2023-05-04 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-05-04
Exact text from the filing
Item 1 – Election of two Class I directors to serve until the Company’s annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified. Votes FOR Votes WITHHELD Broker Non-Votes Michael Amoroso 40,370,180 12,559,294 21,101,108 Geno Germano 38,629,199 14,300,275 21,101,108
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PRECISION BIOSCIENCES INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. at the 2023-05-04 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-05-04
Exact text from the filing
Item 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 72,281,763 1,690,384 58,435 0
View on SEC.gov

Browse all shareholder votes →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR
accession 0000950170-23-019716
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.